RESIDUAL INTRARETINAL EDEMA AFTER 25-GAUGE VITRECTOMY AND MACULAR PUCKER REMOVAL: Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option?

G. Guidi, G. Casini, G. Ripandelli, P. Piaggi, F. Dalle Lucche, M. Sartini, P. Loiudice, F. Nasini, M. Stirpe, S. Lazzeri

Research output: Contribution to journalArticle

Abstract

PURPOSE:: To investigate the efficacy and safety of intraoperative slow-release dexamethasone implant and 25-gauge (G) vitrectomy plus epiretinal membrane removal in patients affected by idiopathic macular pucker. METHODS:: In this randomized, clinical, multicenter study, 60 eyes of 60 pseudophakic eyes having idiopathic macular pucker were enrolled. Thirty eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling (“Control group”), whereas 30 eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling combined with dexamethasone implant (“DEX group”). Best-corrected visual acuity was investigated using Snellen visual acuity ratio. Anatomical outcomes (foveal thickness and total macular volume) were analyzed with spectral domain optical coherence tomography. RESULTS:: After 6-month follow-up, best-corrected visual acuity significantly increased in each group (P <0.05), but there were no significant differences between groups (P = 0.60). Foveal thickness showed a significant decrease in both groups (P <0.05), but no differences were seen between groups (P = 0.80). Finally, also total macular volume decreased significantly in both groups at the last follow-up visit (P <0.05), but both groups a showed similar trend (P = 0.12). CONCLUSIONS:: Intraoperative sustained-release dexamethasone implant, a powerful antiinflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. These data support the hypothesis that its etiology does not seem to be mainly related to an inflammatory process. © 2017 by Ophthalmic Communications Society, Inc.
Original languageEnglish
Pages (from-to)993-999
JournalRetina
Volume38
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Vitrectomy
Dexamethasone
Edema
Visual Acuity
Temazepam
Therapeutics
Epiretinal Membrane
Membranes
Optical Coherence Tomography
Multicenter Studies
Anti-Inflammatory Agents
Communication
Safety
Control Groups

Keywords

  • dexamethasone
  • glucocorticoid
  • aged
  • basement membrane
  • clinical trial
  • controlled study
  • delayed release formulation
  • drug implant
  • female
  • human
  • macular edema
  • male
  • middle aged
  • multicenter study
  • pathology
  • procedures
  • randomized controlled trial
  • retina detachment
  • retina macula lutea
  • retrospective study
  • visual acuity
  • vitrectomy
  • Aged
  • Basement Membrane
  • Delayed-Action Preparations
  • Dexamethasone
  • Drug Implants
  • Female
  • Glucocorticoids
  • Humans
  • Macula Lutea
  • Macular Edema
  • Male
  • Middle Aged
  • Retinal Detachment
  • Retrospective Studies
  • Visual Acuity
  • Vitrectomy

Cite this

RESIDUAL INTRARETINAL EDEMA AFTER 25-GAUGE VITRECTOMY AND MACULAR PUCKER REMOVAL: Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option? / Guidi, G.; Casini, G.; Ripandelli, G.; Piaggi, P.; Dalle Lucche, F.; Sartini, M.; Loiudice, P.; Nasini, F.; Stirpe, M.; Lazzeri, S.

In: Retina, Vol. 38, No. 5, 2018, p. 993-999.

Research output: Contribution to journalArticle

Guidi, G. ; Casini, G. ; Ripandelli, G. ; Piaggi, P. ; Dalle Lucche, F. ; Sartini, M. ; Loiudice, P. ; Nasini, F. ; Stirpe, M. ; Lazzeri, S. / RESIDUAL INTRARETINAL EDEMA AFTER 25-GAUGE VITRECTOMY AND MACULAR PUCKER REMOVAL: Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option?. In: Retina. 2018 ; Vol. 38, No. 5. pp. 993-999.
@article{f5c59fbd75a44f77bdc33505ff03243d,
title = "RESIDUAL INTRARETINAL EDEMA AFTER 25-GAUGE VITRECTOMY AND MACULAR PUCKER REMOVAL: Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option?",
abstract = "PURPOSE:: To investigate the efficacy and safety of intraoperative slow-release dexamethasone implant and 25-gauge (G) vitrectomy plus epiretinal membrane removal in patients affected by idiopathic macular pucker. METHODS:: In this randomized, clinical, multicenter study, 60 eyes of 60 pseudophakic eyes having idiopathic macular pucker were enrolled. Thirty eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling (“Control group”), whereas 30 eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling combined with dexamethasone implant (“DEX group”). Best-corrected visual acuity was investigated using Snellen visual acuity ratio. Anatomical outcomes (foveal thickness and total macular volume) were analyzed with spectral domain optical coherence tomography. RESULTS:: After 6-month follow-up, best-corrected visual acuity significantly increased in each group (P <0.05), but there were no significant differences between groups (P = 0.60). Foveal thickness showed a significant decrease in both groups (P <0.05), but no differences were seen between groups (P = 0.80). Finally, also total macular volume decreased significantly in both groups at the last follow-up visit (P <0.05), but both groups a showed similar trend (P = 0.12). CONCLUSIONS:: Intraoperative sustained-release dexamethasone implant, a powerful antiinflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. These data support the hypothesis that its etiology does not seem to be mainly related to an inflammatory process. {\circledC} 2017 by Ophthalmic Communications Society, Inc.",
keywords = "dexamethasone, glucocorticoid, aged, basement membrane, clinical trial, controlled study, delayed release formulation, drug implant, female, human, macular edema, male, middle aged, multicenter study, pathology, procedures, randomized controlled trial, retina detachment, retina macula lutea, retrospective study, visual acuity, vitrectomy, Aged, Basement Membrane, Delayed-Action Preparations, Dexamethasone, Drug Implants, Female, Glucocorticoids, Humans, Macula Lutea, Macular Edema, Male, Middle Aged, Retinal Detachment, Retrospective Studies, Visual Acuity, Vitrectomy",
author = "G. Guidi and G. Casini and G. Ripandelli and P. Piaggi and {Dalle Lucche}, F. and M. Sartini and P. Loiudice and F. Nasini and M. Stirpe and S. Lazzeri",
note = "Export Date: 25 January 2019 Article in Press CODEN: RETID Correspondence Address: Guidi, G. Chemicals/CAS: dexamethasone, 50-02-2; Delayed-Action Preparations; Dexamethasone; Drug Implants; Glucocorticoids",
year = "2018",
doi = "10.1097/IAE.0000000000001627",
language = "English",
volume = "38",
pages = "993--999",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - RESIDUAL INTRARETINAL EDEMA AFTER 25-GAUGE VITRECTOMY AND MACULAR PUCKER REMOVAL: Is Intraoperative Sustained-release Dexamethasone a Real Treatment Option?

AU - Guidi, G.

AU - Casini, G.

AU - Ripandelli, G.

AU - Piaggi, P.

AU - Dalle Lucche, F.

AU - Sartini, M.

AU - Loiudice, P.

AU - Nasini, F.

AU - Stirpe, M.

AU - Lazzeri, S.

N1 - Export Date: 25 January 2019 Article in Press CODEN: RETID Correspondence Address: Guidi, G. Chemicals/CAS: dexamethasone, 50-02-2; Delayed-Action Preparations; Dexamethasone; Drug Implants; Glucocorticoids

PY - 2018

Y1 - 2018

N2 - PURPOSE:: To investigate the efficacy and safety of intraoperative slow-release dexamethasone implant and 25-gauge (G) vitrectomy plus epiretinal membrane removal in patients affected by idiopathic macular pucker. METHODS:: In this randomized, clinical, multicenter study, 60 eyes of 60 pseudophakic eyes having idiopathic macular pucker were enrolled. Thirty eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling (“Control group”), whereas 30 eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling combined with dexamethasone implant (“DEX group”). Best-corrected visual acuity was investigated using Snellen visual acuity ratio. Anatomical outcomes (foveal thickness and total macular volume) were analyzed with spectral domain optical coherence tomography. RESULTS:: After 6-month follow-up, best-corrected visual acuity significantly increased in each group (P <0.05), but there were no significant differences between groups (P = 0.60). Foveal thickness showed a significant decrease in both groups (P <0.05), but no differences were seen between groups (P = 0.80). Finally, also total macular volume decreased significantly in both groups at the last follow-up visit (P <0.05), but both groups a showed similar trend (P = 0.12). CONCLUSIONS:: Intraoperative sustained-release dexamethasone implant, a powerful antiinflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. These data support the hypothesis that its etiology does not seem to be mainly related to an inflammatory process. © 2017 by Ophthalmic Communications Society, Inc.

AB - PURPOSE:: To investigate the efficacy and safety of intraoperative slow-release dexamethasone implant and 25-gauge (G) vitrectomy plus epiretinal membrane removal in patients affected by idiopathic macular pucker. METHODS:: In this randomized, clinical, multicenter study, 60 eyes of 60 pseudophakic eyes having idiopathic macular pucker were enrolled. Thirty eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling (“Control group”), whereas 30 eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling combined with dexamethasone implant (“DEX group”). Best-corrected visual acuity was investigated using Snellen visual acuity ratio. Anatomical outcomes (foveal thickness and total macular volume) were analyzed with spectral domain optical coherence tomography. RESULTS:: After 6-month follow-up, best-corrected visual acuity significantly increased in each group (P <0.05), but there were no significant differences between groups (P = 0.60). Foveal thickness showed a significant decrease in both groups (P <0.05), but no differences were seen between groups (P = 0.80). Finally, also total macular volume decreased significantly in both groups at the last follow-up visit (P <0.05), but both groups a showed similar trend (P = 0.12). CONCLUSIONS:: Intraoperative sustained-release dexamethasone implant, a powerful antiinflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. These data support the hypothesis that its etiology does not seem to be mainly related to an inflammatory process. © 2017 by Ophthalmic Communications Society, Inc.

KW - dexamethasone

KW - glucocorticoid

KW - aged

KW - basement membrane

KW - clinical trial

KW - controlled study

KW - delayed release formulation

KW - drug implant

KW - female

KW - human

KW - macular edema

KW - male

KW - middle aged

KW - multicenter study

KW - pathology

KW - procedures

KW - randomized controlled trial

KW - retina detachment

KW - retina macula lutea

KW - retrospective study

KW - visual acuity

KW - vitrectomy

KW - Aged

KW - Basement Membrane

KW - Delayed-Action Preparations

KW - Dexamethasone

KW - Drug Implants

KW - Female

KW - Glucocorticoids

KW - Humans

KW - Macula Lutea

KW - Macular Edema

KW - Male

KW - Middle Aged

KW - Retinal Detachment

KW - Retrospective Studies

KW - Visual Acuity

KW - Vitrectomy

U2 - 10.1097/IAE.0000000000001627

DO - 10.1097/IAE.0000000000001627

M3 - Article

VL - 38

SP - 993

EP - 999

JO - Retina

JF - Retina

SN - 0275-004X

IS - 5

ER -